drugset

drugset / Trial / NCT05884320

Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

NCT05884320 ↗

Phase 2 Recruiting 30 enrolled M.D. Anderson Cancer Center Gilead Sciences · collab

RandomizedSingle-groupOpen-labelTreatment

Summary

To learn if sacituzumab govitecan can help to control salivary gland cancer.

Timeline

Start: 2023-07-27
Primary completion: 2028-07-31
Completion: 2028-07-31

Publications

Siqueira JM, Mitani Y, Marques-Piubelli ML, Hoff CO, Bonini F, de Sousa LG, Mitani M, Carvalho GL, Nunes FD, Matos LL, Lin SY, Spiotto MT, Hanna EY, McGrail DJ, El-Naggar AK, Ferrarotto R. TROP2 Expression in Salivary Gland Adenoid Cystic Carcinoma (ACC) According to Histologic Subtype: Therapeutic Implications. J Oral Pathol Med. 2025 Sep;54(8):658-666. doi: 10.1111/jop.70008. Epub 2025 Jul 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sacituzumab Govitecan	Monoclonal antibody	—	Intravenous

Indications